18. Perez-Soler R, Chachoua A, Huberman M, et al. Determinants of tumor
response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol 2004; 22: 3238-47.
19. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated
non–small-cell lung cancer. N Engl J Med 2005; 353: 123-32.
20. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: A phase III trial of erlotinib
hydrochloride (osi-774) combined
with carboplatin and paclitaxel
chemotherapy in advanced non–small-cell lung cancer. J Clin Oncol 2005; 23: 5892-99.
21. Miller VA, Herbst R, Prager D, et al. Long survival of never smoking
non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. J Clin Oncol 22:631S, 2004 (suppl; abstr 7061).
22. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation
with clinical response to gefitinib therapy. Science 2004; 304: 1497-500. 23. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal
growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
24. Shigematsu H, Gazdar A. The epidemiology of EGFR mutations. Signal 2005;
17
6: 4-8.
25. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common
in lung cancers from \smokers\and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-11.
26. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of
non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792. 27. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of
epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23: 2493-501.
28. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth
factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513-20.
29. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor
receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004; 10: 8195-203. 30. Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, et al. Mutation in
the tyrosine kinase domain of epidermal growth factor receptor is a predictive
18
and prognostic factor for gefitinib treatment in patients with non–small cell lung cancer. Clin Cancer Res 2005; 11: 3750-57.
31. Giaccone G. Selection of patients with non-small cell lung cancer for epidermal
growth factor receptor (EGFR) inhibitors: The post-EGFR mutation era. Am Soc Clin Oncol Ed Book 2005: 684-88.
32. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, et
al. Erlotinib in lung cancer – molecular and clinical predictors of outcome. New Engl J Med 2005; 353: 133-44.
33. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al.
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-55.
34. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth
receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005; 23: 6838-45.
35. Mitsudomi T, Yatabe Y. Adenocarcinoma in never-smokers associated with a
lower incidence of genetic alterations. Edu Book of Am Soc Clin Soc 2007; 25: 406-410.
19
36. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung
adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: 1-11.
37. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary
T790M mutations in epidermal growth factor receptor - mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12: 6494-6501.
38. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF
receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005; 102: 7665-70.
39. Sequist LV, Martins RG, Spigel D, et al. iTARGET: A phase II trial to assess
the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors. Proc Am Soc Clin Oncol 2007; 25: a7504.
40. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to
gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-43.
41. Jeffrey Engelman. Strategies to overcome resistance to EGFR inhibitors.
Education session of predicting and targeting drug resistance to tyrosine kinase
20
